Compare DXYZ & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DXYZ | LRMR |
|---|---|---|
| Founded | N/A | N/A |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 563.5M | 455.8M |
| IPO Year | 2024 | 2014 |
| Metric | DXYZ | LRMR |
|---|---|---|
| Price | $29.78 | $4.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | ★ 2.3M | 1.7M |
| Earning Date | N/A | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,816.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.71 | $1.73 |
| 52 Week High | $50.50 | $6.42 |
| Indicator | DXYZ | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 57.71 | 53.86 |
| Support Level | $25.10 | $3.14 |
| Resistance Level | $33.28 | $5.37 |
| Average True Range (ATR) | 2.22 | 0.30 |
| MACD | 0.24 | 0.00 |
| Stochastic Oscillator | 54.98 | 60.09 |
Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It is designed to be an investment portfolio of the Top 100 High-Growth Tech Companies.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.